Collegium Pharmaceutical Q1 2026: Strong Gains & AZSTARYS Acquisition

Collegium Pharmaceuticals Q1 2026 earnings showcase impressive growth, with total net product revenues surging 9% to $193.5 million. JORNAY PM, their ADHD medication, shines with a 14% increase in prescriptions and a 36% rise in revenue to $38.9 million. The pain portfolio contributes $154.6 million, up 4% due to Belbuca and Xtampza ER. The company generated $57.1 million in cash from operations and holds $421.8 million in cash, a 35% increase from year-end. JORNAY gains traction with new highs in prescribers and market share, driven by sales force enhancements and digital campaigns. Collegium secures top rep rankings in ADHD pharma and strengthens their pain med position amid seasonal challenges. In a significant move, theyre acquiring AZSTARYS, an ADHD treatment, for $650 million cash plus potential milestones. The deal closes in Q2, funded by cash and debt, adding over $50 million in second-half revenue and synergies. With patent protection until 2037, Collegium reaffirms guidance for total revenues between $805 million and $825 million, and JORNAY between $190 million and $200 million. The acquisition positions them for ADHD expansion, sustained pain cash flow, and long-term shareholder value creation. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a2b4015c69c712a0